Longeveron (LGVN) Cash from Investing Activities (2020 - 2026)
Longeveron's (LGVN) quarterly Cash from Investing Activities came in at -$20000.0 in Q1 2026, up 86.67% year-on-year from -$10714.3 in Q1 2025, and up 68.75% quarter-over-quarter from -$64000.0 in Q4 2025.
Longeveron (LGVN) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Longeveron's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$20000.0 for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 86.67% year-over-year to -$20000.0 in Q1 2026; TTM through Mar 2026 was -$465000.0, a 42.16% increase from a year earlier, with the FY2025 full-year figure at -$595000.0, up 7.03% from the prior year.
- Cash from Investing Activities advanced to -$20000.0 in Q1 2026 per LGVN's latest filing, from -$64000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $3.8 million in Q3 2023 and bottomed at -$2.4 million in Q3 2022.
- The 5-year median for Cash from Investing Activities is -$53000.0 (2024), against an average of $367882.4.
- Across the five-year window, Cash from Investing Activities soared 374.39% in 2023 and sank 1171.43% in 2025, its largest moves.
- Year by year, Cash from Investing Activities stood at -$570000.0 in 2022, then surged by 374.39% to $1.6 million in 2023, then plunged by 107.86% to -$123000.0 in 2024, then soared by 47.97% to -$64000.0 in 2025, then surged by 68.75% to -$20000.0 in 2026.
- Per Business Quant, the three latest LGVN Cash from Investing Activities figures stand at -$20000.0 (Q1 2026), -$64000.0 (Q4 2025), and -$118000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Longeveron | 15.18 Bn | 15.16 Bn | 264,000.00 | -20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,000.00 |
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -64,000.00 |
| Dec 31, 2025 | -64,000.00 |
| Sep 30, 2025 | -118,000.00 |
| Sep 30, 2025 | -118,000.00 |
| Jun 30, 2025 | -263,000.00 |
| Jun 30, 2025 | -263,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Mar 31, 2025 | -150,000.00 |
| Dec 31, 2024 | -123,000.00 |
| Dec 31, 2024 | -123,000.00 |
| Sep 30, 2024 | -478,000.00 |
| Sep 30, 2024 | -478,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Jun 30, 2024 | -53,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Dec 31, 2023 | 1.56 Mn |
| Dec 31, 2023 | 1.56 Mn |